Personal Home Page

http://www.med.nyu.edu/research/fishmd01.html

Articles in Scholarly Journals [Incomplete List]

1. International variation in rates of uptake of preventive options inBRCA1 andBRCA2 mutation carriers
   International Journal of Cancer, vol. 122, no. 9, pp. 2017–2022, 2008
2. Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner
   Gynecologic Oncology, vol. 108, no. 2, pp. 361–369, 2008
3. S1P and LPA have an attachment-dependent regulatory effect on invasion of epithelial ovarian cancer cells
   Gynecologic Oncology, vol. 107, no. 2, pp. 298–309, 2007
4. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
   The Lancet Oncology, vol. 8, no. 1, pp. 26–34, 2007
5. Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modifications
   PROTEOMICS, vol. 7, no. 22, pp. 4045–4052, 2007
6. Conventional and Proteomic Technologies for the Detection of Early Stage Malignancies: Markers for Ovarian Cancer
   Critical Reviews in Clinical Laboratory Sciences, vol. 44, no. 1, pp. 87–114, 2007
7. A ROBUST BIOMARKER DISCOVERY PIPELINE FOR HIGH-PERFORMANCE MASS SPECTROMETRY DATA
   Journal of Bioinformatics and Computational Biology, vol. 05, no. 05, p. 1023, 2007
8. Amplification of MDS1/EVI1 and EVI1, Located in the 3q26.2 Amplicon, Is Associated with Favorable Patient Prognosis in Ovarian Cancer
   Cancer Research, vol. 67, no. 7, pp. 3074–3084, 2007
9. Engagement of Collagen-Binding Integrins Promotes Matrix Metalloproteinase-9-Dependent E-Cadherin Ectodomain Shedding in Ovarian Carcinoma Cells
   Cancer Research, vol. 67, no. 5, pp. 2030–2039, 2007
10. Lysophosphatidic Acid Down-Regulates Stress Fibers and Up-Regulates Pro-Matrix Metalloproteinase-2 Activation in Ovarian Cancer Cells
    Molecular Cancer Research, vol. 5, no. 2, pp. 121–131, 2007
11. Torg Syndrome Is Caused by Inactivating Mutations in
    Journal of Bone and Mineral Research, vol. 22, no. 2, pp. 329–333, 2007
12. A Novel, High-Throughput Workflow for Discovery and Identification of Serum Carrier Protein-Bound Peptide Biomarker Candidates in Ovarian Cancer Samples
    Clinical Chemistry, vol. 53, no. 6, pp. 1067–1074, 2007
13. Progress in biomarker discovery for diagnostic testing in epithelial ovarian cancer
    Expert Review of Molecular Diagnostics, vol. 6, no. 4, pp. 627–637, 2006
14. Inhibition of Matrilysin Expression by Antisense or RNA Interference Decreases Lysophosphatidic Acid-Induced Epithelial Ovarian Cancer Invasion
    Molecular Cancer Research, vol. 4, no. 11, pp. 831–841, 2006
15. Diagnostic Markers of Ovarian Cancer by High-Throughput Antigen Cloning and Detection on Arrays
    Cancer Research, vol. 66, no. 2, pp. 1181–1190, 2006
16. Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation
    Cancer Letters, vol. 236, no. 2, pp. 292–301, 2006
17. Selective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation
    FEBS Letters, vol. 580, no. 2, pp. 443–449, 2006
18. S1P regulation of ovarian carcinoma invasiveness
    Gynecologic Oncology, vol. 103, no. 3, pp. 952–959, 2006
19. The Tumor Microenvironment: Key to Early Detection
    Critical Reviews in Clinical Laboratory Sciences, vol. 43, no. 5-6, pp. 393–425, 2006
20. Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma
    Molecular & Cellular Proteomics, vol. 4, no. 4, pp. 346–355, 2005
21. Diverse polyubiquitin interaction properties of ubiquitin-associated domains
    Nature Structural & Molecular Biology, vol. 12, no. 8, Article ID nsmb962, 6 pages, 2005
22. Structural Determinants for Selective Recognition of a Lys48-Linked Polyubiquitin Chain by a UBA Domain
    Molecular Cell, vol. 18, no. 6, pp. 687–698, 2005
23. Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis
    Gynecologic Oncology, vol. 96, no. 2, pp. 462–469, 2005
24. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2)
    Gynecologic Oncology, 2005
25. Lysophosphatidic acid inhibits anti-Fas-mediated apoptosis enhanced by actin depolymerization in epithelial ovarian cancer
    FEBS Letters, vol. 579, no. 5, pp. 1311–1319, 2005
26. Lysophosphatidic acid stimulates fas ligand microvesicle release from ovarian cancer cells
    Cancer Immunology, Immunotherapy, vol. 54, no. 8, pp. 807–814, 2005
27. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer
    American Journal of Obstetrics and Gynecology, vol. 192, no. 4, pp. 1214–1221, 2005
28. Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen
    Cancer Letters, vol. 220, no. 1, pp. 57–65, 2005
29. Various strategies of using residual dipolar couplings in NMR-driven protein docking: Application to Lys48-linked di-ubiquitin and validation against15N-relaxation data
    Proteins: Structure, Function, and Bioinformatics, vol. 60, no. 3, pp. 367–381, 2005
30. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase
    International Journal of Cancer, vol. 114, no. 1, pp. 19–31, 2005
31. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases
    International Journal of Cancer, vol. 118, no. 4, pp. 879–888, 2005
32. Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer
    Cancer Epidemiology Biomarkers & Prevention, vol. 14, no. 2, pp. 306–318, 2005
33. Importance of Communication Between Producers and Consumers of Publicly Available Experimental Data
    CancerSpectrum Knowledge Environment, vol. 97, no. 4, pp. 310–314, 2005
34. Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon
    Clinical Cancer Research, vol. 11, no. 17, pp. 6116–6126, 2005
35. Analysis of Albumin-Associated Peptides and Proteins from Ovarian Cancer Patients
    Clinical Chemistry, vol. 51, no. 10, pp. 1933–1945, 2005
36. Clinical Proteomics and Biomarker Discovery
    Annals of the New York Academy of Sciences, vol. 1022, no. 1, pp. 295–305, 2004
37. High-resolution serum proteomic features for ovarian cancer detection
    Endocrine Related Cancer, vol. 11, no. 2, pp. 163–178, 2004
38. Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis
    Clinical Cancer Research, vol. 10, no. 10, pp. 3291–3300, 2004
39. Ubistatins Inhibit Proteasome-Dependent Degradation by Binding the Ubiquitin Chain
    Science, vol. 306, no. 5693, pp. 117–120, 2004
40. Proinvasive Properties of Ovarian Cancer Ascites-Derived Membrane Vesicles
    Cancer Research, vol. 64, no. 19, pp. 7045–7049, 2004
41. Polyubiquitin chains: polymeric protein signals
    Current Opinion in Chemical Biology, vol. 8, no. 6, pp. 610–616, 2004
42. Lessons from Kitty Hawk: From feasibility to routine clinical use for the field of proteomic pattern diagnostics
    PROTEOMICS, vol. 4, no. 8, pp. 2357–2360, 2004
43. Efficient and accurate determination of the overall rotational diffusion tensor of a molecule from 15N relaxation data using computer program ROTDIF
    Journal of Magnetic Resonance, vol. 168, no. 2, pp. 336–345, 2004
44. Telomerase prolongs the lifespan of normal human ovarian surface epithelial cells without inducing neoplastic phenotype
    Journal of the Society for Gynecologic Investigation, vol. 11, no. 8, pp. 553–561, 2004
45. Uterine leiomyosarcoma metastatic to the sphenoid sinus: a case report and review of the literature
    Gynecologic Oncology, vol. 92, no. 2, pp. 701–704, 2004
46. A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians
    Gynecologic Oncology, vol. 93, no. 1, pp. 164–169, 2004
47. Upregulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes
    Gynecologic Oncology, vol. 95, no. 3, pp. 488–495, 2004
48. Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8
    Gynecologic Oncology, vol. 95, no. 2, pp. 314–322, 2004
49. Determining domain orientation in macromolecules by using spin-relaxation and residual dipolar coupling measurements
    Progress in Nuclear Magnetic Resonance Spectroscopy, vol. 44, no. 3-4, pp. 189–214, 2004
50. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers
    Nature Medicine, vol. 10, no. 11, Article ID nm1125, 5 pages, 2004
51. Solution Conformation of Lys63-linked Di-ubiquitin Chain Provides Clues to Functional Diversity of Polyubiquitin Signaling
    Journal of Biological Chemistry, vol. 279, no. 8, pp. 7055–7063, 2003
52. Journal of Biomolecular NMR, vol. 26, no. 2, pp. 181–186, 2003
53. Cancer Causes and Control, vol. 14, no. 5, pp. 439–446, 2003
54. Journal of Biomolecular NMR, vol. 27, no. 3, pp. 261–275, 2003
55. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy⋆
    Gynecologic Oncology, vol. 91, no. 3, pp. 552–557, 2003
56. Direct measurement of the transverse and longitudinal15N chemical shift anisotropy-dipolar cross-correlation rate constants using1H-coupled HSQC spectra
    Magnetic Resonance in Chemistry, vol. 41, no. 10, pp. 837–842, 2003
57. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays
    PROTEOMICS, vol. 3, no. 11, pp. 2085–2090, 2003
58. Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data
    Bioinformatics, vol. 19, no. 13, pp. 1636–1643, 2003
59. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy
    International Journal of Gynecological Cancer, vol. 13, no. 6, pp. 741–748, 2003
60. Localization of the Activin Signal Transduction Components in Normal Human Ovarian Follicles: Implications for Autocrine and Paracrine Signaling in the Ovary
    Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 6, pp. 2644–2657, 2002
61. Structural Properties of Polyubiquitin Chains in Solution
    Journal of Molecular Biology, vol. 324, no. 4, pp. 637–647, 2002
62. Use of proteomic patterns in serum to identify ovarian cancer
    The Lancet, vol. 359, no. 9306, pp. 572–577, 2002
63. Interpreting three new and unique BRCA1 mutations in an Ashkenazi Jewish patient
    Clinical Genetics, vol. 61, no. 4, pp. 317–318, 2002
64. Journal of the American Chemical Society, vol. 123, no. 13, pp. 3021–3036, 2001
65. Tubal ligation and risk of ovarian cancer in carriers of or BRCA2 mutations: a case-control study
    The Lancet, vol. 357, no. 9267, pp. 1467–1470, 2001
66. Three-Dimensional Power Doppler Ultrasound Improves the Diagnostic Accuracy for Ovarian Cancer Prediction*1
    Gynecologic Oncology, vol. 82, no. 1, pp. 40–48, 2001
67. Determination of the Rotational Diffusion Tensor of Macromolecules in Solution from NMR Relaxation Data with a Combination of Exact and Approximate Methods?Application to the Determination of Interdomain Orientation in Multidomain Proteins
    Journal of Magnetic Resonance, vol. 149, no. 2, pp. 204–217, 2001
68. BRCA1 and BRCA2 Mutation Analysis of 208 Ashkenazi Jewish Women with Ovarian Cancer
    The American Journal of Human Genetics, vol. 66, no. 4, pp. 1259–1272, 2000
69. Is Transvaginal Ultrasound Effective for Screening Asymptomatic Women for the Detection of Early-Stage Epithelial Ovarian Carcinoma?
    Gynecologic Oncology, vol. 77, no. 3, pp. 347–349, 2000
70. The Effect of Finite Sampling on the Determination of Orientational Properties: A Theoretical Treatment with Application to Interatomic Vectors in Proteins
    Journal of the American Chemical Society, vol. 122, no. 43, pp. 10640–10649, 2000
71. Solution Structure of the Proapoptotic Molecule BIDA Structural Basis for Apoptotic Agonists and Antagonists
    Cell, vol. 96, no. 5, pp. 625–634, 1999
72. Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment
    Biochemical Journal, vol. 341, no. 3, p. 765, 1999
73. Journal of the American Chemical Society, vol. 121, no. 37, pp. 8577–8582, 1999
74. Journal of Biomolecular NMR, vol. 13, no. 2, pp. 139–147, 1999
75. Journal of the American Chemical Society, vol. 120, no. 28, pp. 7109–7110, 1998
76. Journal of the American Chemical Society, vol. 120, no. 42, pp. 10947–10952, 1998
77. Management of Twin Pregnancies Consisting of a Complete Hydatidiform Mole and Normal Fetus
    Obstetrics & Gynecology, vol. 91, no. 4, pp. 546–550, 1998
78. Ectopic Pregnancy Causing Hemothorax Managed by Thoracoscopy and Actinomycin D
    Obstetrics & Gynecology, vol. 91, no. 5, pp. 837–838, 1998
79. Perceptions of Cisplatin-Related Toxicity among Ovarian Cancer Patients and Gynecologic Oncologists
    Gynecologic Oncology, vol. 71, no. 3, pp. 369–375, 1998
80. Metastatic Dissemination of Human Ovarian Epithelial Carcinoma Is Promoted by α2β1-Integrin-Mediated Interaction with Type I Collagen
    Invasion and Metastasis, vol. 18, no. 1, pp. 15–26, 1998
81. What Happens After Discharge? Return Hospital Visits After Ambulatory Surgery
    Anesthesia & Analgesia, vol. 84, no. 2, pp. 319–324, 1997
82. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells
    Cancer, vol. 80, no. 8, pp. 1457–1463, 1997
83. Ovarian Carcinoma Initially Presenting as Metastatic Axillary Lymphadenopathy
    Gynecologic Oncology, vol. 65, no. 3, pp. 543–547, 1997
84. Ovarian Carcinoma Metastatic to the Choroid of the Eye
    Gynecologic Oncology, vol. 65, no. 3, pp. 517–519, 1997
85. Endometrial Adenocarcinoma Metastatic to the Scalp: Case Report and Literature Review
    Gynecologic Oncology, vol. 65, no. 3, pp. 530–533, 1997
86. Biochemical Characterization of Primary Peritoneal Carcinoma Cell Adhesion, Migration, and Proteinase Activity
    Gynecologic Oncology, vol. 67, no. 2, pp. 193–199, 1997
87. Journal of the American Chemical Society, vol. 119, no. 23, pp. 5321–5328, 1997
88. Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the Endometrium
    Gynecologic Oncology, vol. 61, no. 2, pp. 189–196, 1996
89. Late Recurrences of Vaginal Clear Cell Adenocarcinoma
    Gynecologic Oncology, vol. 62, no. 1, pp. 128–132, 1996
90. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the αA2β1 integrin
    International Journal of Cancer, vol. 67, no. 5, pp. 695–701, 1996
91. Backbone dynamics of proteins studied by two-dimensional heteronuclear NMR spectroscopy and molecular dynamics simulations
    International Journal of Quantum Chemistry, vol. 59, no. 4, pp. 291–300, 1996
92. Extramammary Paget's Disease of the Vulva
    Gynecologic Oncology, vol. 56, no. 2, pp. 266–270, 1995
93. Effect of Combination Chemotherapy with Cisplatin and Cyclophosphamide on Human Immunodeficiency Virus Type-1 Surrogate Markers in a Patient with Advanced Epithelial Ovarian Cancer
    Gynecologic Oncology, vol. 57, no. 1, pp. 105–108, 1995
94. Design and performance of externally modulated 1.5- mu m laser transmitter in the presence of chromatic dispersion
    Journal of Lightwave Technology, vol. 11, no. 4, pp. 624–632, 1993
95. Optical fibre up-taper back-reflector for laser transmitter evaluation
    Electronics Letters, vol. 24, no. 23, p. 1417, 1988
96. Kinetic Properties of the Two-Level Systems in Glasses with Account of Tunneling
    physica status solidi (b), vol. 127, no. 2, pp. 679–688, 1985